niacinamide has been researched along with Carcinoma, Transitional Cell in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sorafenib is a multi-kinase inhibitor that targets rapidly accelerated fibrosarcoma (RAF), vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-β (PDGFR-β), and KIT." | 4.12 | Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. ( Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T, 2022) |
| " However, some studies have been stopped owing to the development of severe adverse events." | 2.80 | Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer. ( Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yokota, S | 1 |
| Yonezawa, T | 1 |
| Momoi, Y | 1 |
| Maeda, S | 1 |
| Miyata, Y | 1 |
| Asai, A | 1 |
| Mitsunari, K | 1 |
| Matsuo, T | 1 |
| Ohba, K | 1 |
| Sakai, H | 1 |
| Pham, MN | 1 |
| Apolo, AB | 1 |
| De Santis, M | 1 |
| Galsky, MD | 1 |
| Leibovich, BC | 1 |
| Pisters, LL | 1 |
| Siefker-Radtke, AO | 1 |
| Sonpavde, G | 1 |
| Steinberg, GD | 1 |
| Sternberg, CN | 1 |
| Tagawa, ST | 1 |
| Weizer, AZ | 1 |
| Woods, ME | 1 |
| Milowsky, MI | 1 |
| Vom Dorp, F | 1 |
| Börgermann, C | 1 |
| Rose, A | 1 |
| Becker, M | 1 |
| Rübben, H | 1 |
| Hoskin, PJ | 2 |
| Rojas, AM | 2 |
| Saunders, MI | 2 |
| Bentzen, SM | 1 |
| Motohashi, KJ | 1 |
| Dreicer, R | 1 |
| Li, H | 1 |
| Stein, M | 1 |
| DiPaola, R | 1 |
| Eleff, M | 1 |
| Roth, BJ | 1 |
| Wilding, G | 1 |
| Phillips, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer[NCT00033436] | Phase 3 | 330 participants (Anticipated) | Interventional | 2000-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2017 |
4 trials available for niacinamide and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxy | 2015 |
Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Transitional Cell; Dose Fractionation, Radiation | 2009 |
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Transitional Cell; Disease-Free Surviv | 2009 |
Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce | 2005 |
2 other studies available for niacinamide and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; | 2022 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |